Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lingping Kong
Observed names:
Ling-Ping Kong,
Ling-ping Kong
Institution:
Tianjin Medical University General Hospital
Observed institutions:
Tianjin Medical University General Hospital,
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0002-2399-2212
Observed ORCID:
0000-0002-2399-2212
OpenAlex ID:
A5102994816
Long Non Coding RNA MALAT1 Promotes Tumor Growth and Metastasis by inducing Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma
2015
·
Xuan Zhou
, Su Liu
, et al.
·
Scientific Reports
·
238
PDF
STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
2018
·
Shanshan Sun
, Yansheng Wu
, et al.
·
Clinical Cancer Research
·
98
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
2024
·
Lingping Kong
, Fanlu Meng
, et al.
·
中国科学通报:英文版
·
56
WP1066 Sensitizes Oral Squamous Cell Carcinoma Cells to Cisplatin by Targeting STAT3/miR-21 axis
2014
·
Xuan Zhou
, Yu Ren
, et al.
·
Scientific Reports
·
54
PDF
Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC
2015
·
Xuan Zhou
, Yu Ren
, et al.
·
Oncotarget
·
50
PDF
Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC
2023
·
Lingping Kong
, Fanlu Meng
, et al.
·
Clinical and Translational Medicine
·
47
PDF
Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion
2018
·
Yu Wang
, Wenyu Guo
, et al.
·
International Journal of Oncology
·
47
PDF
Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis
2019
·
Minghui Zhao
, Xiaomeng Hu
, et al.
·
International Journal of Oncology
·
33
PDF
The Protective Effects of Crocetin on Aβ1-42-Induced Toxicity in Ht22 Cells
2014
·
Yan Kong
, Ling-Ping Kong
, et al.
·
CNS & Neurological Disorders - Drug Targets
·
27
Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer
2021
·
Xing-mei Liang
, Qiong Qin
, et al.
·
Acta Pharmacologica Sinica
·
25
PDF
A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma.
2019
·
Zhaoqing Li
, Tingting Zhu
, et al.
·
PubMed
·
21
Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
2022
·
Qing Ma
, Lingping Kong
, et al.
·
Frontiers in Oncology
·
14
PDF
Nomogram for predicting opioid-induced nausea and vomiting for cancer pain patients
2023
·
Lingping Kong
, Jing Wang
, et al.
·
Supportive Care in Cancer
·
6
PDF
[Research Progress of Klotho in Lung Neoplasms].
2023
·
Jing Wang
, Lili Zeng
, et al.
·
PubMed Central
·
2
PDF
Case Report: Observational use of mycophenolate mofetil in probable steroid-unresponsive immune checkpoint inhibitor-associated transverse myelitis
2026
·
Lingping Kong
, Xin Wang
, et al.
·
Frontiers in Immunology
·
1
PDF
Mycophenolate mofetil for corticosteroid-resistant immune-related cystitis associated with tislelizumab: a case report
2026
·
Lingping Kong
, Fanlu Meng
, et al.
·
Frontiers in Immunology
·
1
PDF
[Retracted] Role of the EZH2/miR‑200 axis in STAT3‑mediated OSCC invasion
2025
·
Yu Wang
, Wenyu Guo
, et al.
·
International Journal of Oncology
·
1
PDF
[Corrigendum] Role of the EZH2/miR‑200 axis in STAT3‑mediated OSCC invasion
2023
·
Yu Wang
, Wenyu Guo
, et al.
·
International Journal of Oncology
·
1
PDF
ATR inhibition potentiates immunotherapy efficacy via TBK1-NFκB signaling and autophagy blockade in non-small cell lung cancer
2026
·
Guo Li
, Lingping Kong
, et al.
·
Cancer Immunology Immunotherapy
Relationship between tumor markers and overall survival in small cell lung cancer: a retrospective cohort study
2026
·
Li Yan
, Shasha Guan
, et al.
·
Journal of Thoracic Disease
Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
2025
·
Lingping Kong
, Lina Peng
, et al.
·
Frontiers in Oncology
PDF
Abstract 5231: Case report: dramatic response to Crizotinib in a patient with synchronous multiple primary lung cancer positive for a novel ARL1-MET fusion
2022
·
Qing Ma
, Lingping Kong
, et al.
·
Cancer Research
Additional file 3: Figure S1. of Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma
2015
·
Sun, Shan-Shan
, Zhou, Xuan
, et al.
·
Figshare
Show more works
View as search
Works count:
23
Citation count:
722
H-index:
12
I10-index:
12
Year
Topic
Type